Proteologics

Company Overview

Snapshot

Founded in May 1999 by Uriel (Uri) Halavee and Gleb Zilberstein, Proteologics operates with 1–10 employees. The company raised $25,000,000 across one funding round. Proteologics was acquired by Zmiha Investment House Ltd. in September 2013.

Business overview

Proteologics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for cancer treatment. The company leverages the ubiquitin system, specifically identifying correlations between ubiquitin pathway components and pathological conditions, to discover inhibitors for specific E3 ubiquitin ligases. Proteologics operates within the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals and Drugs Discovery & Development, serving the life sciences and pharmaceutical industries.

Strategic signal

In September 2013, Zmiha Investment House Ltd. acquired control of Proteologics from XTL Biopharmaceuticals Ltd. for NIS 12.1 million, including a control premium. This acquisition marked a significant strategic shift for Proteologics, leading to the freezing of its research activities, while its stocks continued to be traded on the TASE. This event signals a transition from active biopharmaceutical research and development to a holding company structure under new ownership.

Company Intelligence Q&A

When was Proteologics founded?

Proteologics was founded in May 1999 by Uriel (Uri) Halavee and Gleb Zilberstein.

What is Proteologics' primary focus?

Proteologics focuses on exploiting the ubiquitin system for the discovery and development of novel therapeutics for cancer treatment, specifically by discovering inhibitors for specific E3 ubiquitin ligases.

What was a significant corporate event for Proteologics in 2013?

In September 2013, Proteologics was acquired by Zmiha Investment House Ltd. This acquisition led to the company freezing its research activity.

What was the total capital raised by Proteologics?

Proteologics raised a total of $25,000,000 across one funding round.

What is the current status of Proteologics?

Proteologics is currently in an 'Acquired (Inactive)' status, following its acquisition by Zmiha Investment House Ltd. in September 2013.